I think that’s essentially probably correct Biosect. Bigger is stating once NWBO gets the application submitted, there is every reason for them to turn their attention and energies toward unlocking further value pent up in the DC library of tumor antigens worth pursuing.
He doesn’t want them sitting on their hands while they wait for a regulatory decision, he wants them pursuing additional value provided by their technologies.
They’ve used the excuse long enough that they first need to get L submitted before pursuing other matters like DCVax-Direct, and Bigger wants to make certain they don’t stand around while waiting for the regulatory decisions.
To me, it’s a positive development.
News 
Market Data 
Discover 
AI
